ARDSNet01 version 2 Annotated CRFs Table of Contents

Form	Page
ALI SCREENING (Day 0)	001
INCLUSION CRITERIA (Day 0)	003
EXCLUSION CRITERIA (Day 0)	
APACHE III DEMOGRAPHICS (Day 0)	006
APACHE III PHYSIOLOGY (Day 0)	007
APACHE - ABG (Day 0)	
VITAL SIGNS (Day 0)	
CHEST X-RAY / BAROTRAUMA (Day 0)	010
MEDICATION REPORT (Day 0)	
GLASGOW COMA (Day 0)	011
VENTILATOR PARAMETERS (Day 0)	012
ON STUDY VITAL SIGNS (Day 1)	013
ON STUDY VENTILATOR PARAMETERS (Day 1)	
CHEST X-RAY / BAROTRAUMA (Day 1)	
MEDICATION REPORT (Day 1)	
WEANING / DRUG DISCONTINUATION (Day 1)	
BRUSSELS TABLE (All Days)	
SPECIMEN COLLECTION (All Days)	
ADVERSE EVENT REPORT (All Days)	021
STUDY TERMINATION (All Days)	
ADDITIONAL COMMENTS (All Days)	

Part 01:04	ALI SCREENING	NHLBI-9404	Day: 0
Copy:	Investigator:	Patie	nt ID:
+1. Acute Onset 2. Within past - PaO2/FiO2 - Bilateral frontal of - Receiving 3. No clinical pulmonary of 4. PaO2: 5. FiO2:	OR PATIENTS MEETING CE 24 hrs patient had Al 2 less than or equal to 3 infiltrates consister 3 positive pressure ver 4 evidence of left Atri 6 arterial wedge pressure 8 that all these criter	LL of the following 300 mmHg? Int with pulmonary Intilation via endial hypertension Interes or = 18 mmHg)	1=Yes, 2=No: SCK ng? 1=Yes, 2=No: SCK edema on otracheal tube? (if measured ? 1=Yes, 2=No: SCK PAO2 FIO2
		 NHLBI-9404	
	Investigator:		ent ID:
8. Gender 9. Ethnicity Hispanic 5=America 10. Age: 11. Location	spital ID #: NOTE: how	spid field removed from 1=Male, 2= ic Origin, 2=Black sian/Pacific Isla ve, 6=Other: c SICU, 4=CCU, 5=Ne	database Hospid Female: GENDER ander, ETHNIC AGE Euro ICU, Local
.ge ID: [101]		-	Print Count: [1]

Electronic Table Name = SCREEN

Part 03:04	ALI SCREENII	NG NHLBI-9404	Day: 0
Сору:	Investigator:	Pati	ent ID:
13. Primary 0=Not Exclu 3=Patient U 5=Other Tri 7=Neuromusc 10=Chronic 13=Bone/Lun 15=Treated 16=Treated	Reason for Exclusion: ded, 1=MD Refuses, 2=1 nable/Surrogate Unava- al 30 days, 6=Inclusion ular Disease, 8=Patien Lung Disease, 11=Burn g Transplant, 14=Not on with Itraconazole, Keto with Astemizole, Terfer Liver Disease, 18=Acur e Allergy s:	Patient/Family Refilable, 4=Patient on Criteria > 36 hot Pregnant, 9=Incommitted to Full oconazole, Fluconazole, Cisapride P	REASON uses, < 18 Years, ours, reased ICP, al Illness, Support, ole Past 7 days, ast 3 days,
Part 04:04	ALI SCREENI		
Trauma: Aspirat	ury Category (0=None, TRAUMA Sepsis ion:ASPR Pneumonia Description: OTHTXT	1=Primary, 2=Seco : <u>S</u> EPS\S Multipl :PNEUM	ondary) Le Transfusion: MULT Other: OTHE
15. Date of	IG ITEMS ARE NOT REQUI unassisted breathing ed for greater than 48	if unassisted brea	ENTERED IN KARMA athing UNASSIS
16. Date of	Discharge from Study	Hospital	DISCH
17. Status a	at Discharge from Stud	ly Hospital 1=	=Alive,2=Dead: DISS
been masked, du	of the data originally entered e to the sensitive nature of the ons document (01-03_change	ese data. Please refer to	• • •
		:	
ge ID: [101]		Print Count: [2

Electronic Table Name = SCREEN

Part	01:01	INCLUSION CRITERI	A NHLBI-9404	Day: 0
Сору		Investigator:	Patient	: ID:
1=Yes	s,2=No:			Date: <u>VDATE</u>
INCLI 1	. Acute 0	nset		
	- PaO2/F - Bilate fronta - Receiv . No clin pulmona	the past 24 hours did p iO2 less than or equal ral infiltrates consist I chest radiograph? ring positive pressure v dical evidence of left a ary arterial wedge press	to 300 mmHg? cent with pulmonary ventilation via end atrial hypertension sure < or = 18 mmHg	y edema on dotracheal tube? n (if measured
		INCLL	1DE	

Print Count: [4]

Part 01	:04	EXCLUSION	CRITERIA	NHLBI-9404	Day: 0
Сору	_:Inve	stigator:		Patien	t ID:
1=Yes,2					Date: <u>VDATE</u>
3441 1 N	ttending nh	veician un	willing to	participate?	
V/12 2. P	atient unwi	lling to pa	articipate?	•	
x433. U	nable to ob	tain infor	med consent	?	
<u>x444. I</u>	s patient 1	ess than 1	8 years old	[? : intormontion	trials in AT.T
<u>:χ</u> <u>ζ</u> ζζ 5 . Η	as patient PDS or Sens	participat sis within	ed in other the past 30	davs?	trials in ALI,
EXCL66. H	as it been	> 36 hours	since all	inclusion crit	eria were met?
EXCL77. D	oes the pat	cient have	neuromuscu]	ar disease tha	t impairs the
		ventilate s	pontaneous	Ly?	
EXCLAS. I	s patient p	riegnant:	elevated IO	P, tricyclic a	ntidepressant
6 <u>xc</u> c(). D	verdose, H	GBSS, HGBSC	, or other	conditions whe	ere hypercapnia
W	ould be con	ntraindicat	ed?	•	•
€× <u>(U</u> 010.D	oes patient	t have seve	re chronic	respiratory di	sease:
			·		
Part 02	2:04	EXCLUSION	CRITERIA	NHLBI-9404	Day: 0
Copy	: Inv	estigator:		Patie	nt ID:
Copy		estigator: 		Patie	nt ID:
1=Yes,2	2=No:				
1=Yes,2	2=No: Does patie	nt have bui		Patien than or equal	
1=Yes,2	2=No: Does patie body surfa Does patie	nt have bui ce area? nt have a i	rns greater	than or equal or other chron	to 30% total ic irreversible
1=Yes,2	2=No: Does patie body surfa Does patie disease or	nt have bunce area? Int have a recondition	rns greater malignancy for which	than or equal or other chron	
1=Yes,; Exc <u>l</u> i(11. Exc <u>l</u> (212.	Does patie body surfa Does patie disease or at greater	nt have bunce area? Int have a recondition than 50%?	rns greater malignancy for which	than or equal or other chron 6 month mortal	to 30% total ic irreversible ity is estimated
1=Yes,; Excli 11. Excli 212.	Does patie body surfa Does patie disease or at greater Has the pa	nt have bunce area? Int have a recondition than 50%?	rns greater malignancy for which	than or equal or other chron 6 month mortal	to 30% total ic irreversible
1=Yes, 2 EXCLI 11. EXCL 1212. EXCL 1313.	Does patie body surfa Does patie disease or at greater Has the pa transplant	nt have bunce area? Int have a recondition than 50%? Itient had areas	rns greater malignancy for which either a bo	than or equal or other chron 6 month mortal ne marrow tran	to 30% total ic irreversible ity is estimated splant or lung
1=Yes, 2 EXCLI 11. EXCL 1212. EXCL 1313.	Does patie body surfa Does patie disease or at greater Has the patransplant Not commit	nt have bunce area? Int have a recondition than 50%? Itient had exercised to fullatient been	rns greater malignancy for which either a bo l support? treated wi	than or equal or other chron 6 month mortal ne marrow tran th ketoconazol	to 30% total ic irreversible ity is estimated splant or lung
1=Yes, 2 EXCLI 11. EXCLI 212. EXCLI 313. EXCLI 4 14. EXCLI 4 15.	Does patient body surfate Does patient disease or at greater Has the patient Not commits that the patient patient between the between	nt have bunce area? Int have a recondition than 50%? Itient had expected to full atient been to the term to the te	rns greater malignancy for which either a bo l support? treated wi he past 7 o	than or equal or other chron 6 month mortal ne marrow tran th ketoconazol	to 30% total ic irreversible ity is estimated splant or lung e, itraconazole,
1=Yes, 2 EXCLI 11. EXCLI 212. EXCLI 313. EXCLI 4 14. EXCLI 4 15.	Does patient body surfated body surfated boes patient disease or at greater has the patransplant Not commit has the patransplant has the patransplant becomes	nt have bunce area? Int have a recondition than 50%? Itient had expected to full atient been to the term to the te	rns greater malignancy for which either a bo l support? treated wi he past 7 o	than or equal or other chron 6 month mortal ne marrow tran th ketoconazol lays? th astemizole,	to 30% total ic irreversible ity is estimated splant or lung
1=Yes, 2 EXCLI 11. EXCLID12. EXCLID13. EXCLID 14. EXCLID 15.	Does patient body surfate Does patient disease or at greater Has the patransplant Not commit Has the patransplant Has the patransplant Consequence of the patransplant Has the pa	nt have burded area? Int have a read to than 50%? It ient had a condition that the the the the the the the the the th	rns greater malignancy for which either a bo l support? treated wi he past 7 o treated wi past 3 day	than or equal or other chron 6 month mortal ne marrow tran th ketoconazol lays? th astemizole,	to 30% total ic irreversible ity is estimated splant or lung e, itraconazole, terfenadine, or
1=Yes, 2 EXCLI 11. EXCLI 212. EXCL 313. EXCL 9 14. EXCL 15 15. EXCL 16 16.	Does patient body surfated bod	nt have bunce area? Int have a recondition than 50%? It tent had expected to full attent been been within the within the om the EXCLU	rns greater malignancy for which either a bo 1 support? treated wi he past 7 o treated wi past 3 day DE' table have	than or equal or other chron 6 month mortal ne marrow tran th ketoconazol lays? th astemizole, rs?	to 30% total ic irreversible ity is estimated splant or lung e, itraconazole, terfenadine, or
1=Yes, 2 EXCLI 11. EXCL 1212. EXCL 1313. EXCL 14 14. EXCL 15 15. EXCL 1616.	Does patient body surfated bod	nt have bunce area? Int have a recondition than 50%? It tent had expected to full attent been been within the within the om the EXCLU	rns greater malignancy for which either a bo 1 support? treated wi he past 7 o treated wi past 3 day DE' table have	than or equal or other chron 6 month mortal ne marrow tran th ketoconazol lays? th astemizole,	to 30% total ic irreversible ity is estimated splant or lung e, itraconazole, terfenadine, or

Part 03:04	EXCLUSION	CRITERIA	NHLBI-9404	Day: 0
Copy:	Investigator: _		Patient	ID:
No Abnorm	ality		e I or II,3=Grade	ent,3=Tense: <u>P</u> UGL e III or IV: <u>P</u> UGL
span; le change o Grade II stimuli; bizarre or witho C. Bilirubin D. Albumin (E. Prothromb 1=Yes,2=No: XCL1717. Is pati	thargy; disorie r inappropriate or IV - very d confused; gros behavior; coma; ut abnormal mov (mg/dl) g/dl) in time (sec. p ent known to ha	ntation in behavior rowsy; ser s disorier unrespond ements 1= rolonged) we severe	[>3.5],2=[2.8-3.	rsonality esponsive to or space; stimuli with 2-3],3=[>3]:PUGH 5],3=[<2.8]:PUGH 10],3=[>10]:PUGH Total:PUGH
		, , , , , , , , , , , , , , , , , , ,		· · ·
Part 04:04	EXCLUSION	CRITERIA		Day: 0
Copy:	<pre>Investigator: _</pre>	·	Patient	ID:
toxic land	nepatitis with retient have knownives? patient morbid HE ABOVE ANSWERS formed consent lease call	oderate of allergy ly obese? S ARE YES been obtained the study for random	of acute viral, r severe hepatoc to imidazole or (weight(kg)/heig PATIENT SHOULD Named? ly and consent ha omization number. system prompts	ellular injury? its ht(cm)>1) OT BE ENROLLED as been obtained,
23. Patien 24. Date/t	t randomized to ime of initial	(1=6 r ventilator	nl/kg,2=12 ml/kg) change: <u>Excl3301</u>	EXCL22 EXCL23TM
	F.X	CLUPE		
age ID: [103]	• .		P	rint Count: [5
	ata from the 'EXCLU in compliance with n		ve not been included i	n the limited

Part 01:02	APACHE III	DEMOGRAPHICS	NHLBI-9404	Day:	0
Сору:	Investigator		Patient II	o:	
3=ER. 4=Fl	ion Date: U Admission: mitted Directi oor, 5=Anothe	ly From 1=0R,2= r Special Care	-Recovery Room, Unit, -Stepdown Unit:	Date: <u>VDA</u> HADMI ICUDI ILUTA ADMFR	<u>DT</u>
5. If immedia 6. ICU Readmi 7. ICU Readmi 8a. Is chroni 8b. Is the pa 9a. AIDS (do	tely post-ope t: t within 24 h c health info tient on chro not include H	rative, was sur ours: rmation availar nic dialysis on IV positive wit	rgery elective?:	l=Yes,? lysis?: ria):	
					·
				Dozza	 -
Part 02:02	APACHE III	DEMOGRAPHICS			
Copy:	Investigator	:	Patient I	D:	
				1=Yes,	2=No:
9d. Solid tur 9e. Immune su	cin's Lymphoma nor with metas uppression (ra than or equal	stasis: adiation, chemo	otherapy or 'day prednisone	:	TUMOR IMMUNI
or equi	valent) within failure with o s:	n the past 6 mo	onths:		HEPA CIRR QCAB
				•	

Print Count: [3]

Part 01:02	APACHE III P	HYSIOLOGY N	HLBI-9404	Day: 0
Copy: Inv	vestigator:		Patient I	D:
+USE VALUES FROM VITAL SIGNS +1. Temperature: 2. Systolic BP: 3. Mean Arteria. 4. Heart Rate: 5. Respiratory 6a. Was patient when the low rate occured 6b. Was patient when the high	24HRS PRECEDI Pressure: Rate: Rate: Ventilated est respirator ? 1=Yes, 2=No: ventilated hest respirator ? 1=Yes, 2=No:	NG INITIAL VE LOWEST High FEMPCL TEMP SYSBPL SYSBI NE ANAPL MEANA HRATEL HRATE RESPL RESPI Y LYENT OTY HYENT	NT CHANGES est Lowes CHC TEMPFL PH mmHg PH mmHg H beats/min	Date: VDATE t Highest TEMPFHF
+/. Urine Output	/24 nours:	<u>UK)</u>	<u>M₽</u> mī	
			·	·
Part 02:02	APACHE III I			
Copy:_ In	vestigator: _		Patient I	D:
USE VAL HEMATOLOGY *8. Hct: *9. WBC: *10.Platelets	UES FROM 24HRS	Lowest	Highest HCTH & WBCH /mm	
*11. Serum Sod *12. Serum Pot *13. Serum BUN *14. Serum Cre *15. Serum Glu *16. Serum Alb *17. Serum Bil *18. Serum Bic	assium: (highest): atinine: cose: bumin: irubin (highe	SODIUML POTASL CREATL GLUCL ALBUML st): BICAR	SOPIUMIA meq/ POTASH meq/ BUN mg/c CREATH mg/c GLUCH mg/c ALBUMH g/dl BILL mg/c	'L 31 31 31 31 4

Electronic Table Name = PHYSIO

Page ID: [105]

Print Count: [4]

Page ID: [106]

Part	01:02	AI	PACHE - ABG	NHLBI	-9404	Day: 0
Сору	-	Investiga	ator:		Patient II	D:
10.	F102 F1021 F1023 F1024 F1025 F1026 F1027 F1028 F1029 F10216	ALL ABG'S PaO2 mmHg PAO21 PAO22 PAO24 PAO24 PAO25 PAO26 PAO26 PAO29 PAO216	PaCO2 mmHg PACO21 PACO22 PACO23 PACO24 PACO25 PACO26 PACO26 PACO27 PACO27 PACO29 PACO210	PH 1 PH 2 PH 3 PH 4 PH 5 PH 6 PH 7 PH 9 PH 9 PH 16	Visit DING INITIAL VEI Intubated when I 1=Yes, 2= INTU INTU INT	ABG obtained =No -BAT1 VBAT2 UBAT3 VBAT5 VBAT5 VBAT6 BAT7 BAT7 BAT7 BAT7
==== Part	02:02	 A	======================================	NHLB	 I-9404	 Day: 0
Сору		Investig	ator:		Patient I	D:
1 1 1 1 1 1 1	Fi02 1.FI0211 2.FI0212 3.FI0213 4.FI0214 5.PI0215 6.FI0216 7.FI0217 8.PI0218 9.FI0219 20.FI0224	PaO2 mmHg PAO210 PAO210 PAO213 PAO214 PAO215 PAO216 PAO217 PAO218 PAO219	PaCO2 mmHg PACO211 PACO212 PACO213 PACO214 PACO215 PACO216 PACO217 PACO219 PACO219 PACO224	PH 12 PH 13 PH 15 PH 16 PH 16 PH 16 PH 16 PH 19 PH 20	Intubated when 1=Yes, /N/I /N/I /N/I /N/I /N/I /N/I /N/I /N	ABG obtained

NOTE: the original production of the data extract tables combined the above variables into: fio2, pao2, paco2, ph, and intubate, as you can see in the electronic 'babg' table you have received. No data were altered as a result of this restructuring.

Electronic Table Name = BABG

Print Count: [5]

Part 01:02	VITAL SIGNS	NHLBI-9404	Day: 0
Copy: Investi	gator:	Pati	ent ID:
1 Date and time of c	urrent intubat	ion: INTUBDT	Date: VPATE
2. Heart Rate: 3. Systolic BP: 4. Diastolic BP: 5. Temperature: 6. Height 7. Gender: 8. IBW: 9. Weight: 10.Fluid Intake/24 ho	SYSBP MODIABP MODIABP MODIABP MODIABP MODIABP CONTROL		
	VITAL SIGNS	NHLBI-9404	Day: 0
Copy: Invest:		•	lent ID:
+ITH 11. Hct: 12. WBC: 13. Total Bilirubin: 14. AST: 15. ALT: 16. Alkaline Phospha	HCT WBC BILL AST ALT	mg/dl Units/L Units/L	HRS
+Collect blood for p.	r cytokines and rior to initial	l urine for thro vent change	mboxane metabolites
NOTE that this baseline 'Vital the electronic 'vital' table that		th the on-study 'Vital'	form (page 13) to create

Electronic Table Name = VITAL

Page ID: [107]

Part 01:01	CHEST X-RAY/BAROTR	AUMA NHLBI-9404	Day:0
Copy:	Investigator:	Patient I	D:
1	MOST RECENT CXR PRIOR T	Da O INITIAL VENT CHANG	ite: <u>VDATE</u> E
1. Radiograph	nic Lung Injury Score (# of quadrants 0-4)	AADLIS
Pneumomed:	races 1=Rig ous emphysema	1=	=Yes,2=No: $\overline{\beta}$ AR δ
3. Chest Tub	e 1=Rig	ght,2=Left,3=Bilatera	al,4=None: <u>C</u> TVB
	paseline Chest XRay form was electronic 'oschest' table that y	•	est XRay form (page
	OSC HE		
Part 01:01	MEDICATION REP		Day: 0
Copy :		Patient 1	
	OST RECENT WITHIN 24HRS	S Initial Vent Chang	Date: VDATE ge Time: VENTCHTT
	ve/Tranquilizers	arbiturates,propofol)
LOCAER2. Neurom 18μος 3. H2 Blo 110π 4. Erythr	uscular Blocking Agent:	, or other macrolide	antibiotics t 24 hrs.?
LOCKER 2. Neurom 12810ch 3. H2 Blo VIB <u>r</u> o 4. Erythr AS <u>OP</u> 5. Has pa	uscular Blocking Agents ckers? comycin, clarithromycin	, or other macrolide opressors in the pas	t 24 hrs.?
LOCKER 2. Neurom 128LOCK 3. H2 Blo VYBIO 4. Erythr ASOP 5. Has pa STUDY I	nuscular Blocking Agents ockers? comycin, clarithromycin atient received any vas	, or other macrolide opressors in the pas ED WITHIN 4HRS OF RA	t 24 hrs.? NDOMIZATION (6D)

MED

Part	01:01	GLASGOW	COMA	NHLBI-9404	Day:	0
Copy	/:	_ Investigator: _		Patier	nt ID:	
					Date: <u>// ()</u>	ATE
1.	Is patie If yes,	nt on a sedative o use best estimate	r neuro	omuscular blocker	? 1=Yes,2=No:	SEDATE
2.	Eye Open	ing Score 4=Sponta	neous,	3=To Voice, 2=To	Pain, 1=None	: EYE
3.]	Motor Re 6=Obeys	sponse Score Commands, 5=Locali al Flexion, 2=Exte	zes to	Pain, 4=Flexor W		MOTOR
	5=Orient 4=Confus 3=Inappr	-	OR	On Ventilator 5=Appears Orie 3=Quesionably 1=Generally Un	Oriented, responsive	<u>V</u> ERBAL L:_ <u>TO</u> TAL
			·	·	·	

GLASGON

Page ID: [108]

Part 01:02	VEN	TILATOR	PARAMET	ERS	NHLBI-9404		Day:	0
Сору:	Investi	gator: _			Patien	t ID:		
3=Servo 3		turer ar 7200, 2= milton \	nd Model =Servo 9 /eolar/	Initia L: VMC 3000, Amadeus	1 Vent Char DEL	E Da [.] ige Tii	te: <u>VD</u> me: <u>VE</u> N	ATE L IC HTI
2. Ventilate	or Mode st/Control RV ed Deliver	1=Yes,2 1=Yes,2 1=Yes,2 ed Tidal	2=No: 2=No: 2=No: 1 Volume	2.2 Pr 2.4 Pr 2.6 Ot	ressure Supressure Cont her 1=Yes, 2 ml	zror r	=res,∠= C	=No: Ps =No: Ps OTHERS
(If on P. 5. Pressure	ressure Co	ntrol Ve	entilati	ion) P <u>SU</u> P				
		:			:=====================================			
 Part 02:02	VEN	TILATOR	PARAME'	 TERS	NHLBI-9404		Day:	0
Pstat #	Investi spiratory nute Venti Pressure 1 0.5 second 2 0.5 second 3 0.5 second spiratory	Rate: lation: ond end- ond end- ond end- ond end- Pressur Set I:E	inspira inspira inspira	tory pa		bre bre L/m cm mmi	H20 H20 H20 H20 H20 H20 H20 H20	 in.

NOTE that this baseline 'Vent' form was joined with the on-study 'Vent' form (page 14) to create the electronic 'vent' table that you have received.

Part 01:02	ON S	STUDY VITAL	SIGNS	NHLBI-9404	Day:	1
Сору:_	Investi	gator:		Patien	t ID:	
119e t	he value clo	osest to 08	:00. It	:00. If more not available riod on same	in referenc	ue, e
	ic BP: olic BP: cature:	ours: FLUIDI	mmHg mmHg C 1 K kg W	EMPFL F EIGHTL 1bs		·
						1
Part 02:03	2 ON 	STUDY VITA	L SIGNS	NHLBI-9404	Day:	
Сору:	Investi	gator:		Patier 	nt ID:	
8. Hct: 9. WBC: 10. AST: 11. ALT: 12. Alka	line Phospha	AST AL	/mm Uni Uni	^3 ts/L ts/L ts/L		
+Collect on Days	1 + 3; coll	lect blood	ior Keto	for thromboxan levels 2 houn ollection form	rs arter bay	3 3
	s on-study 'Vital' al' table that you	-		baseline 'Vital' forr	n (page 9) to crea	ate the
		_,	_ _ _ _			

Page ID: [202]

Part 01:02 ON STUDY VENTILATOR PARAMETERS NHLBI-9	
Copy: Investigator: Patier	nt ID:
IF ON POSITIVE PRESSURE VENT DURING REFERENCE PERIOD 0600-1000. IF MORE THAN ONE VALUE, USE VALUES CLOSES TO 0800. IF ABG NOT AVAILABLE IN REFERENCE PERIOD, US CLOSEST TO REFERENCE PERIOD ON SAME CALENDAR DATE. 1. Ventilator Manufacturer and Model: VMODEL 1=Puritan-Bennett 7200, 2=Servo 9000, 3=Servo 300, 4=Hammilton Veolar/Amadeus, 5=Bird 8400, 6=Bear 1000, 7=Other 2. Ventilator Mode 2.1 Assist/Control 1=Yes, 2=No: ASSIST 2.2 Pressure Support 1=Yes, 2=No: PSUPP 2.3 Unassisted Breathing 1=Yes, 2=No: UNASIS +3. Calculated Delivered Tidal Volume: TIDAL ml (If on Volume Cycled Mode) +4. Pressure Support: (If on Pressure Support Ventilation)	Date: <u>VDATE</u> SE
Part 02:02 ON STUDY VENTILATOR PARAMETERS NHLBI-	9404 Day: 1
	breaths/min. breaths/min. L/min cm H2O cm H2O cm H2O cm H2O cm H2O cm H2O mmH2O mmHg mmHg
Copy : Investigator: Patie 5. Set Rate: SRATE 6. Total Respiratory Rate: TRESPR 7. Total Minute Ventilation: TMNVNI 8. PEEP: FEEF 9. Plateau Pressure Pstat #1 0.5 second end-inspiratory pause: PSTAT Pstat #2 0.5 second end-inspiratory pause: PSTAT Pstat #3 0.5 second end-inspiratory pause: PSTAT Pstat #3 0.5 second end-inspiratory pause: PSTAT 10. Peak Inspiratory Pressure: PEAK 11. I:E Ratio: a.Set I:E RATIO: PROPER b. True I:ETRANO: 12. Mean Airway Pressure: MAPRE 13. FiO2: +14. PaO2: +15. PaCO2: +16. Arterial pH:	breaths/min. breaths/min. L/min cm H2O cm H2O cm H2O cm H2O cm H2O cm H2O mmH2O mmHg mmHg

NOTE that this on-study 'Vent' form was joined with the baseline 'Vent' form (page 12) to create the electronic 'vent' table that you have received.

Print Count: [8]

Electronic Table Name = VENT

Conv	01:01		BAROTRAUMA NHLBI-9404	Day:1
COPA .	•	Investigator:	Patient ID:	
Us			Date: <u>//</u> ence period 06:00-10:00. If unav use first CXR this calendar day.	ailable
			core (# of quadrants 0-4)	B <u>A</u> DLIS
Pne Sul Pne	eumomedia	ices is emphysema istinum	1=Right, 2=Left, 3=Bilateral, 4=No 1=Yes, 2= 1=Yes, 2= 1=Right, 2=Left, 3=Bilateral, 4=No	=no: <u>B</u> a <i>ro</i> 2 =no: Bar <i>o</i> 3
	est Tube		1=Right, 2=Left, 3=Bilateral, 4=No	
			m was joined with the baseline Chest XRay le that you have received.	form (page
			SCHEST	
				
Part 	01:01		CON REPORT NHLBI-9404	Day:1
Сору	:	Investigator:	Patient ID:	
			ANY OF THE FOLLOWING Date ISTERED THIS CALENDAR DAY	e: VDATE
	IMDICAL	•		
- OCHER2.	Sedative (benzod: Neuromus H2 Block	e/Tranquilizers iazepines,narcot scular Blocking kers?	tics,barbiturates,propofol) Ağents	
- C <u>h</u> er2. B <u>lo</u> ch3. E <u>TO</u> 4a	Sedative (benzod: Neuromus H2 Block THE I	e/Tranquilizers iazepines,narcot scular Blocking kers? FOLLOWING DRUGS nazole PLUC 4b. 1 FOLLOWING DRUGS	tics, barbiturates, propofol) Agents ARE DISCOURAGED BY THE PROTOCOL Fluconazole ITRA 4c. Itraconazol ARE PROHIBITED BY THE PROTOCOL Terfenadine CISA 5c. Cisapride	
Cher2. Block3. ETO 4a STEM 5a TRIC 6a Cno 7a	Sedative (benzod: Neuromus H2 Block THE 1 1. Ketocon THE 1 1. Astemis	e/Tranquilizers iazepines,narcot scular Blocking kers? FOLLOWING DRUGS nazole FLUC 4b. 1 FOLLOWING DRUGS zole FERF 5b. 5 EXPER: oxide JUNF 6b. 5	tics, barbiturates, propofol) Agents ARE DISCOURAGED BY THE PROTOCOL Fluconazole ITRA 4c. Itraconazol ARE PROHIBITED BY THE PROTOCOL Terfenadine CISA 5c. Cisapride IMENTAL THERAPIES Surfactant PARTLU 6c. Partial Liq	e
Cher2. BLOCK 3. ETO 4a STEP 5a TRIC 6a CONE 76	Sedative (benzod: Neuromus H2 Block THE I A. Ketocom THE I A. Astemis A. Nitric A. ECMO I. Prone	e/Tranquilizers iazepines,narcot scular Blocking kers? FOLLOWING DRUGS nazole FLUC 4b. 1 FOLLOWING DRUGS zole JERF 5b. 5 EXPERIOXIDE 6b. 5 LVOX 7b. 1	tics, barbiturates, propofol) Agents ARE DISCOURAGED BY THE PROTOCOL Fluconazole ITRA 4c. Itraconazol ARE PROHIBITED BY THE PROTOCOL Terfenadine CISA 5c. Cisapride IMENTAL THERAPIES Surfactant PARTLU 6c. Partial Liq	e uid Vent.
Cher2. BLOCK 3. ETO 4a STEP 5a TRIC 6a CONE 76	Sedative (benzod: Neuromus H2 Block THE I A. Ketocom THE I A. Astemis A. Nitric A. ECMO I. Prone	e/Tranquilizers iazepines,narcot scular Blocking kers? FOLLOWING DRUGS nazole FLUC 4b. 1 FOLLOWING DRUGS zole JERF 5b. 5 EXPERIOXIDE 6b. 5 LVOX 7b. 1	tics, barbiturates, propofol) Agents ARE DISCOURAGED BY THE PROTOCOL Fluconazole ITRA 4c. Itraconazol ARE PROHIBITED BY THE PROTOCOL Terfenadine CISA 5c. Cisapride IMENTAL THERAPIES Surfactant PARILU 6c. Partial Liq IVOX HEVAFO 7c. HEV or HEO omycin, or other macrolide antib	e uid Vent.
Cher2. 8Lock 3. Eto 4a TRIC 6a Chi 7a Cone 7a	Sedative (benzod: Neuromus H2 Block THE I Ketocon THE I Astemi: Nitric ECMO Prone Erythro	e/Tranquilizers iazepines,narcot scular Blocking kers? FOLLOWING DRUGS nazole FLUC 4b. 1 FOLLOWING DRUGS zole JERF 5b. 5 EXPERIOXIDE 6b. 5 LVOX 7b. 1	tics, barbiturates, propofol) Agents ARE DISCOURAGED BY THE PROTOCOL Fluconazole ITRA 4c. Itraconazol ARE PROHIBITED BY THE PROTOCOL Terfenadine CISA 5c. Cisapride IMENTAL THERAPIES Surfactant PARTLU 6c. Partial Liq IVOX AFUNEO 7c. HFV or HFO	e uid Vent. iotics

Print Count: [9]

Page ID: [204]

Part 01:04 WEANING/DRUG DISCONTINUATION N	HLBI-9404 Day:1
Copy: Investigator:	Patient ID:
DURING THE SAME CALENDAR DAY	
 +1a. Was the patient permanently withdrawn from arm of the protocol? +1b. Was the patient permanently withdrawn from arm of the protocol? 2. Was study drug administered? 3. At 0600, was patient on: ωΕΑ2Ν 1=Volume Assist/Control Ventilation 2=Pres 3=Unassisted Breathing 4=Othe ωΕΑ2ΝΟ 	1=Yes, 2=No: VWVRNW the keto/placebo 1=Yes, 2=No: KWDRAW 1=Yes, 2=No: WEALN ssure Support Ventilation
NOTE that variable 'WEA2NO' has been removed from the limited access dataset, to maintain non-identifiability. 4. Did patient meet weaning evaluation criter 4a. If 4 is Yes, did patient pass 5 minute CPA	ia? WEA3N
_## 	
Part 02:04 WEANING/DRUG DISCONTINUATION N	NHLBI-9404 Day:1
Copy: Investigator:	Patient ID:
5. Were there attempts to wean PS by 5cmH2O?	1=Yes, 2=No: WEA5CM
If No, why not: WEASTXT	NOTE that variable 'WEA5TXT' has been removed from the limited access dataset, to maintain non-identifiability
WEANING HISTORY: Record initial and subsequent levels along with their corresponding starting	t Pressure Support
Pressure Support level is changed. Pressure Support Level Time Pressure State Time State	Support Level Time LEVELB TIMEB -EVELD TIMED LEVELF TIMEF -EVELH TIMEH

Electronic Table Name = WEAN

Investigator:	Part 03:04	WEANING/DRUG DIS	SCONTINUATION NHLBI-9404	Day:1
6. Did patient tolerate a trial of spontaneous breathing > 2 hours? 1=Yes,2=No.3=Not tried/Evaluated: weak! 7. Did patient complete 48 hours of unassisted breathing on this calendar day? For items 9 through 13 enter first value in 4 hr interval ON or AFTER time of the ventilator check. If no time appears, skip items 8 - 15. Selected Time of ventilator check: VENTCK TM 18. Was patient on assist/control continuously during 4 hrs preceding and 4 hrs following selected ventilator check time? 1=Yes,2=No: ASSIS 9. FiO2: 10. Calculated Delivered Tidal Volume: TIDAL ml 11. PEEP: 12. Set Rate: 12. Set Rate: 13. Pplat Mid PLAT cm H2O Patient ID: For items 14 and 15 enter last value in the four hour interval ON OR PRIOR TO time of the ventilator check 14a. pH: 14b. If PH available, was set rate changed in the interval between measurement and the time set rate (Item 11) recorded? 1=Yes,2=No:SETC: 15a. SpO2: 15b. If SpO2 available, was FiO2 or PEEP changed in the interval between interval between SpO2 measurement and the time FiO2 or PEEP (Items 9 or 11) recorded? NOTE that the electronic table WEAN' also contains the following variables: ventcm2, pao2, peechng, noph, and volin. These were added as the ARDSNet03 CRFs were developed. To view the corresponding questions that were used with these variables, please refer to the annotated Weaning form for ARDSNet03	Copy:	Investigator:	Patient ID:	
For items 14 and 15 enter last value in the four hour interval ON OR PRIOR TO time of the ventilator check 14a. pH: 14b. If PH available, was set rate changed in the interval between measurement and the time set rate (Item 11) recorded? 1=Yes, 2=No:SETC) 15a. Sp02: 15b. If Sp02 available, was Fi02 or PEEP changed in the interval between Sp02 measurement and the time Fi02 or PEEP (Items 9 or 11) recorded? NOTE that the electronic table 'WEAN' also contains the following variables: ventctm2, pao2, peechng, noph, and volin. These were added as the ARDSNet03 CRFs were developed. To view the corresponding questions that were used with these variables, please refer to the annotated Weaning form for ARDSNet03	7. Did patien this calen For items 9 t time of the v 8. Was patie and 4 hrs 9. FiO2: 10. Calculate 11. PEEP: 12. Set Rate: 13. Pplat Mic	t tolerate a trial t complete 48 hours dar day? hrough 13 enter fin entilator check. Selected Time of v ent on assist/contro following selected d Delivered Tidal	of spontaneous breathing > 1=Yes, 2=No, 3=Not tried/E s of unassisted breathing of 1= rst value in 4 hr interval If no time appears, skip it ventilator check: VENTCKTN ol continuously during 4 hr d ventilator check time? 1= FIOZ Volume: TIDAL ml PEEP cm H2O SRATE PPLAT cm H2O	2 hours? valuated: wealn n Yes, 2=No: weath ON or AFTER ems 8 - 15. % s preceding Yes, 2=No: ASSIST
For items 14 and 15 enter last value in the four hour interval ON OR PRIOR TO time of the ventilator check 14a. pH: 14b. If PH available, was set rate changed in the interval between measurement and the time set rate (Item 11) recorded? 1=Yes, 2=No:SETC) 15a. SpO2: 15b. If SpO2 available, was FiO2 or PEEP changed in the interval between SpO2 measurement and the time FiO2 or PEEP (Items 9 or 11) recorded? NOTE that the electronic table 'WEAN' also contains the following variables: ventctm2, pao2, peechng, noph, and volin. These were added as the ARDSNetO3 CRFs were developed. To view the corresponding questions that were used with these variables, please refer to the annotated Weaning form for ARDSNetO3	Part 04:04	WEANING/DRUG DI		
ON OR PRIOR TO time of the ventilator check 14a. pH: 14b. If PH available, was set rate changed in the interval between measurement and the time set rate (Item 11) recorded? 1=Yes, 2=No:SETC! 15a. SpO2: 15b. If SpO2 available, was FiO2 or PEEP changed in the interval between SpO2 measurement and the time FiO2 or PEEP (Items 9 or 11) recorded? NOTE that the electronic table 'WEAN' also contains the following variables: ventctm2, pao2, peechng, noph, and volin. These were added as the ARDSNetO3 CRFs were developed. To view the corresponding questions that were used with these variables, please refer to the annotated Weaning form for ARDSNetO3	Copy:	Investigator:	Patient ID:	
14b. If PH available, was set rate changed in the interval between measurement and the time set rate (Item 11) recorded? 1=Yes, 2=No:5£TC! 15a. Sp02: 15b. If Sp02 available, was FiO2 or PEEP changed in the interval between Sp02 measurement and the time FiO2 or PEEP (Items 9 or 11) recorded? NOTE that the electronic table 'WEAN' also contains the following variables: ventctm2, pao2, peechng, noph, and volin. These were added as the ARDSNet03 CRFs were developed. To view the corresponding questions that were used with these variables, please refer to the annotated Weaning form for ARDSNet03	For items			interval
NOTE that the electronic table 'WEAN' also contains the following variables: ventctm2, pao2, peechng, noph, and volin. These were added as the ARDSNet03 CRFs were developed. To view the corresponding questions that were used with these variables, please refer to the annotated Weaning form for ARDSNet03	14b. If PH a measurement 15a. SpO2: 15b. If SpO2 interval bet	and the time set available, was Fi ween SpO2 measurem	rate changed in the intervarate (Item 11) recorded? 1= SPOZ % O2 or PEEP changed in the lent and the time FiO2 or PE	=Yes,2=No:5 <u>七</u> (Ch) CEP
	NOTE that the ventctm2, pao2 CRFs were developed these variables	electronic table 'WEAN' al 2, peechng, noph, and voli veloped. To view the corre 5, please refer to the annot	Iso contains the following variables: n. These were added as the ARDSN esponding questions that were used were the contact were used we	let03

Electronic Table Name = WEAN

Part 01:02	BRUSSELS	TABLE	DAYS 0-14	NHLBI-9404		Day:	ALL
Copy:	Investiga	ator:	· · · · · · · · · · · · · · · · · · ·	Patie	nt ID:		
Date Day 0.5 VOATE Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 10 Day 11 Day 12	Syst BP	FiO2	X 1000 PLATIES	inine CREATO 2 3 4 5 7 10 10	Bili- rubin BILIO 1 2 3 4 5 6 7 8 9 10 11	1=¥	ressor ,2=N VASO12
							·
Part 02:02	BRUSSELS	TABLE	DAYS 0-14	NHLBI-940	4	Day:	ALL
Copy:	Investig	ator:		Pati	ent ID:		
Day 13 Day 14	Syst	FiO2	Χ 1000 ι3ι	inine	Bili- rubin	1=	pressor =Y,2=N _ (3 _ 14

Copy	Part 01:01 F	RUSSELS TABL	E DAYS 15-28	NHLBI-9404	Day: ALL
Date BP FiO2 X 1000 inine rubin 1=Y,2=N Day 15 VARIEO SURPE PARTO PLATES CREATO BILLO VASO D Day 16	Copy:	Investigator:		Patient ID:	
Day 20	Date Day 15 Day 16 Day 17 Day 17 Day 18 Day 19 Day 20 Day 21 Day 22 Day 23 Day 24 Day 25 Day 26 Day 27 Lite	BP FiO2 5'44P6 PAFZ	X 1000	inine rubin	1=Y,2=N

BAUSS

NOTE: the original production of the data extract tables combined the above variables into: vdate, sysbp, pafi, plate, creat, bili, and vaso, as you can see in the electronic 'bruss' table you have received. No data were altered as a result of this restructuring.

Part 01:01 SPECI	MEN COLLECTION	NHLBI-9404	Day: ALL
Copy: Investigate	or:	Patient	ID:
Day 0 Blood for cytokine Urine for Thromboxane M Day 1 Blood for cytokine Urine for Thromboxane M Day 3 Blood for cytokine Urine for Thromboxane M	- β <u>1</u> 0002 etab υ <u>R</u> INE2 β <u>1</u> 0003	Date BLDT1 URDT1 BLDT2 URDT3 URDT3	Date: <u>VDATE</u>
Study Drug given Time Study Drug given Blood for Ketoconazole Time	5T <u>D</u> AVG BL <u>CO</u> DK	STDAUGOT STDAUGTM BLOKEM BLOKEM	

SPEC

Date: VOATE 1. Date of event: EVDBTE 2. Time of event: EVTA	3. Specified event: SPEVINT 1=Increased Intracranial Pr 3=Arrhythmia 4=Hep Other Specify: OTHER 4. Describe event or problem: OESC	ressure patitis	e of event:	Date: VO EVIN nal Bleed event	ATE .
1. Date of event: APPE 2. Time of event: EVIT 3. Specified event: SPEWT 1=Increased Intracranial Pressure 3=Arrhythmia 4=Hepatitis 5=Other adverse event Other Specify: OTHER NOTE that variables OTHER and DESC' 4. Describe event or problem: OESC 5. Severity of event (1=mild,2=moderate,3=severe): 6. Did AE require therapeutic intervention to prevent permanent impairment/damage? (1=Yes,2=No): Part 02:02 ADVERSE EVENT REPORT NHLBI-9404 Day: ALL Copy : Investigator: Patient ID: 1=Yes,2=No 7. Was the patient in immediate risk of death due to the event? 8. Did the patient die as a result of the event? 9. Was the event unexpected in ARDS or more severe or frequent than expected in ARDS? (1=yes,2=no,3=unknown): 1-definitely associated 2=probably associated 3=possible associated 4=probably not associated 5=definitely not associated 6=uncertain association 5=definitely not associated 6=uncertain association 5=definitely not associated 6=uncertain association 1. Was study drug discontinued as a result of this event? 12. Was patient withdrawn from the ventilator because of event? 13. Outcome to date: 1=recovered - date: RECOT 2=AE present, no treatment 2-Probably treated 4=residual effect/no treatment	3. Specified event: SPEVNT 1=Increased Intracranial Pr 3=Arrhythmia 4=Hep Other Specify: OTHER 4. Describe event or problem:	ressure patitis	2=Gastrointesti	nal Bleed	STE_
3=Arrhythmia 0ther Specify: OTHER 1 NOTE that variables NOTE that variables OTHER and DESC OTHER AND DESCRIPTION D	3=Arrhythmia 4=Hep Other Specify: OTHER 4. Describe event or problem:	patitis		event	
Part 02:02 ADVERSE EVENT REPORT NHLBI-9404 Day: ALL Copy : Investigator: Patient ID: 1=Yes, 2=No 7. Was the patient in immediate risk of death due to the event? RISAL 8. Did the patient die as a result of the event? 9. Was the event unexpected in ARDS or more severe or frequent than expected in ARDS? (1=yes, 2=no, 3=unknown): 1-245 1-25				'OTHER' and not included in limited acces in compliance non-identifiate requirements	l 'DESC' in the s datase e with pility
The stigator: Patient ID:	6. Did AE require therapeutic	interve	ntion to prevent		
1=Yes, 2=No 7. Was the patient in immediate risk of death due to the event? 8. Did the patient die as a result of the event? 9. Was the event unexpected in ARDS or more severe or frequent than expected in ARDS? (1=yes, 2=no, 3=unknown): 10. Causal relationship to study drug: 1=definitely associated 2=probably associated 3=possible association 4=probably not associated 5=definitely not associated 6=uncertain association 11. Was study drug discontinued as a result of this event? 12. Was patient withdrawn from the ventilator because of event? 13. Outcome to date: 1=recovered - date: RECOI 2=AE present, no treatment 3=AE present/being treated 4=residual effect/no treatment					
	8. Did the patient die as a re 9. Was the event unexpected in than expected in ARDS? (1=y 10. Causal relationship to stude 1=definitely associated 3=possible associated 3=possible association 5=definitely not associated 11. Was study drug discontinuous 12. Was patient withdrawn from 13. Outcome to date: 1=recovered - date: RECOI 3=AE present/being treated	esult of n ARDS or yes, 2=no udy drug: 2= 4= d 6= ed as a r m the ven	the event? more severe or , 3=unknown): probably associa probably not ass uncertain associ esult of this ev tilator because AE present, no t residual effect,	frequent ted sociated ation rent? of event?	BISH I DIE EXPERIENTED IN COUTCO

NOTE that the electronic database 'AER' also contains the following variables: system1, system2, failure, msof, and death. Please refer to the Summary of Changes document (01-03_changes.pdf) for a description of these variables.

Print Count: [73]

Part 01:02	STUDY TERM	MINATION	NHLBI-9404		Day: ALL
Copy:_	Investigator:		Pati	ent ID:	
breathing 48 hours o after day breathing, 30 days un any locati 1. Patient 1=Home 2=Dead	with unassisted brea prior to discharge h	comes fired breathing discharge t's status the patiessisted branch thing ome with the come of	ing at home rst). For ped home or sat intervent survive reathing.	with unassi for more tatients ali are on assi als of at meass so the second sec	chan ve sted lost at e = 'status'
3=Other 1a.If 1, d 1b.If 2, d	prior to achieving unate discharged home late of death: late of last patient	on unassi	_	ing: 5	TIDT T2.0T 5730T
Part 02:02	STUDY TER	MINATION	NHLBI-9404	<u> </u>	Day:ALL
Copy:_	Investigator: _		Pati	ent ID:	
ing for 2a.If Yes, 3. Did the first 2 3a.If Yes, quired 4. Was the first 2 4a.If Yes, 5. Did the 28 days 5a.If Yes receive 6. Patient	able to sustain a particular date of patient return to a second of calendar assisted breathing be patient discharged as days after enrolling date of discharge: a patient return to a second of calendar as patient return to a second of calendar and ICU-care between the discharge and	ing first eriod of ssisted b dates on etween the alive from ICU durates on the dates on study	28 days? I unassisted reathing du which the pe date 2a am ICU during the firm which the period to 4a and and a hospital?	t=Yes,2=No: breathing: breathing: bring the t=Yes,2=No: batient re- and day 28: ng the t=Yes,2=No: cst t=Yes,2=No: patient day 28:	breath- UNASSIST UNAOT ASSIST ASDAYS ICU ICUDT BICU RICUDAYS ALIVE ALIVEDT
	ì	ERM		•	

Part 01:01	ADDITIONAL COMMENTS	NHLBI-9404	Day: ALL
Copy:_	_ Investigator:	Patient]	ID:
Form Name: Item Number: Day Number:	FRNAME ITEMNUM DAYNUM		Date: VDATE
Comment:			
		•	
÷			
	COMMENT	<u> </u>	

NOTE that the data from the 'COMMENT' table have not been included in the limited access dataset, in compliance with non-identifiability requirements.